188 related articles for article (PubMed ID: 34533824)
61. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
62. Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis.
Patel NG; Lindsey T; Strunk RC; DeBaun MR
Pediatr Blood Cancer; 2010 Sep; 55(3):554-6. PubMed ID: 20658630
[TBL] [Abstract][Full Text] [Related]
63. Relationship of Opioid Prescriptions to Physical Therapy Referral and Participation for Medicaid Patients with New-Onset Low Back Pain.
Thackeray A; Hess R; Dorius J; Brodke D; Fritz J
J Am Board Fam Med; 2017; 30(6):784-794. PubMed ID: 29180553
[TBL] [Abstract][Full Text] [Related]
64. Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents - Selected U.S. States, 2019.
Schieve LA; Simmons GM; Payne AB; Abe K; Hsu LL; Hulihan M; Pope S; Rhie S; Dupervil B; Hooper WC
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1241-1246. PubMed ID: 36173745
[TBL] [Abstract][Full Text] [Related]
65. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
66. Medication adherence among pediatric patients with sickle cell disease: a systematic review.
Walsh KE; Cutrona SL; Kavanagh PL; Crosby LE; Malone C; Lobner K; Bundy DG
Pediatrics; 2014 Dec; 134(6):1175-83. PubMed ID: 25404717
[TBL] [Abstract][Full Text] [Related]
67. Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability.
Ryan N; Dike L; Ojo T; Vieira D; Nnodu O; Gyamfi J; Peprah E
BMJ Open; 2020 Nov; 10(11):e038685. PubMed ID: 33168553
[TBL] [Abstract][Full Text] [Related]
68. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
69. Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease.
Creary SE; Modi AC; Stanek JR; Chisolm DJ; O'Brien SH; Nwankwo C; Crosby LE
J Pediatr Psychol; 2019 Nov; 44(10):1196-1204. PubMed ID: 31403687
[TBL] [Abstract][Full Text] [Related]
70. Clinical and socio-demographic determinants of pentazocine misuse among patients with sickle cell disease, Benin City, Nigeria: a case-control study.
Adewoyin A; Adeyemi O; Davies N; Ojo M
Pan Afr Med J; 2019; 34():88. PubMed ID: 31934231
[TBL] [Abstract][Full Text] [Related]
71. Depression and anxiety in adults with sickle cell disease: the PiSCES project.
Levenson JL; McClish DK; Dahman BA; Bovbjerg VE; de A Citero V; Penberthy LT; Aisiku IP; Roberts JD; Roseff SD; Smith WR
Psychosom Med; 2008 Feb; 70(2):192-6. PubMed ID: 18158366
[TBL] [Abstract][Full Text] [Related]
72. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
[TBL] [Abstract][Full Text] [Related]
73. Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease.
Badawy SM; Thompson AA; Liem RI
Pediatr Blood Cancer; 2016 May; 63(5):848-52. PubMed ID: 26844685
[TBL] [Abstract][Full Text] [Related]
74. Quality of life assessments in a cohort of Mozambican children with sickle cell disease.
Issa F; Dang BN; Buck WC; Chicumbe S; Nicolau N; Virate C; Cassamo N; Dias A; Amodo F
Pan Afr Med J; 2020; 36():343. PubMed ID: 33224409
[TBL] [Abstract][Full Text] [Related]
75. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
76. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
[TBL] [Abstract][Full Text] [Related]
77. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
[TBL] [Abstract][Full Text] [Related]
78. Beliefs about hydroxyurea in youth with sickle cell disease.
Badawy SM; Thompson AA; Liem RI
Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):142-148. PubMed ID: 29397333
[TBL] [Abstract][Full Text] [Related]
79. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
Ritho J; Liu H; Hartzema AG; Lottenberg R
Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
[No Abstract] [Full Text] [Related]
80. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Barbu EA; Dominical VM; Mendelsohn L; Thein SL
PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
